We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Threshold Pharmaceuticals's financial performance into perspective.
Jun 13, 2017
Threshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and Ipilimumab
May 15, 2017
Jun 13, 2017 at 4:15 PM ET
Mar 17, 2017